HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Regulatory reform

This article was originally published in The Rose Sheet

Executive Summary

Regulatory reform: Senate Governmental Affairs Committee expected to markup a moderate regulatory reform bill March 15. The measure will likely be based on S 291, drafted by Committee Chairman William Roth (R-DE), but will include elements of two other regulatory bills introduced by Sens. Robert Dole (R-KS) and John Glenn (D-OH). Administration officials expressed cautious support for S 291 during a March 8 committee hearing, particularly its definition of a "major" rule affected by the bill, provisions on judiciary review and its exclusion of existing laws. A "major" rule would have an annual effect on the economy of $100 mil. or more...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel